Padagis, a US-based pharmaceutical manufacturer that offers generic Rx and OTC products, announced on Tuesday the first-to-market launch of an AB-rated generic version of Zomig Nasal Spray.
The product is distributed in a unique unit dose presentation and is used to treat migraine headaches with or without aura in adults and paediatric patients (12 to 17 years of age).
Padagis president and chief executive officer, Sharon Kochan, said, 'This first-to-market launch is our second major product launch as an independent organisation since our separation from Perrigo in July and highlights our ongoing commitment and capabilities to develop, manufacture and commercialise high quality, high value alternatives in important treatment categories. The Padagis team continues to leverage our unique and specialised manufacturing technologies and development expertise to deliver valuable products to our customers and patients.'
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US